AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT03976869
- Locations
- 🇺🇸
Research Site, Murray, Utah, United States
A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9
- Registration Number
- NCT03971110
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Tezepelumab Home Use Study
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: Tezepelumab (AI)Biological: Tezepelumab (APFS)
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 216
- Registration Number
- NCT03968978
- Locations
- 🇵🇱
Research Site, Wrocław, Poland
Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE. A Descriptive Analysis of the Asthma Patient Population in the Emirate of Dubai With Respect to Healthcare Resource Utilization, Costs, and Asthma-related Treatment Pattern
Completed
- Conditions
- Asthma
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40541
- Registration Number
- NCT03963141
- Locations
- 🇦🇪
Dha Claim, Dubai, United Arab Emirates
Open-label Extension Study of Brazikumab in Crohn's Disease
Phase 3
Terminated
- Conditions
- Crohn's DiseaseIBD
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT03961815
- Locations
- 🇨🇳
Research Site, Taichung, Taiwan
A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 925
- Registration Number
- NCT03959488
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 81
- Registration Number
- NCT03953300
- Locations
- 🇬🇧
Research Site, Wythenshawe, United Kingdom
Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers
Phase 1
Completed
- Conditions
- Cardiovascular Disease
- Interventions
- Drug: [14C]AZD5718 Oral Suspension
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT03948451
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Phase 2
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 247
- Registration Number
- NCT03944772
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)
Phase 1
Completed
- Conditions
- Relative Bioavailability
- Interventions
- Drug: BDA MDI 160/180 mcg
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT03934333
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath